Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.86 |
| ▸ | HPGD | P15428 | 3/20 | 0.86 |
| ▸ | POLB | P06746 | 1/20 | 0.86 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | NCF1 | P14598 | 2/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351521 | 1.00 | KDM4E (1.00) | KDM4EGAAL3MBTL1ACHEALDH1A1 | |
| SCHEMBL26723750 | 0.98 | KDM4E (1.00) | KDM4EGAAL3MBTL1ACHEALDH1A1 | |
| SCHEMBL6509689 | 0.86 | KMT2A (0.78) | KDM4EGAAL3MBTL1ACHEALDH1A1 | |
| SCHEMBL5910282 | 0.86 | KMT2A (1.00) | KDM4EGAAL3MBTL1ACHEALDH1A1 | |
| SCHEMBL5912926 | 0.86 | NCF1 (0.89) | KDM4EGAAL3MBTL1ACHEALDH1A1 | |
| SCHEMBL4821642 | 0.84 | NCF1 (1.00) | KDM4EGAAL3MBTL1ACHEALDH1A1 | |
| SCHEMBL19051441 | 0.84 | KDM4E (1.00) | KDM4EGAAL3MBTL1ACHEALDH1A1 | |
| SCHEMBL5910684 | 0.82 | KMT2A (0.72) | KDM4EGAAL3MBTL1ACHEALDH1A1 | |
| SCHEMBL23206051 | 0.81 | KDM4E (0.69) | KDM4EGAAL3MBTL1ACHEALDH1A1 | |
| SCHEMBL28803647 | 0.81 | HTR3A (0.73) | KDM4EGAAL3MBTL1ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131634-B2 | Method of treating pain | POSEIDA THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | claimed |
| EP-2790687-B1 | TRPC4 MODULATORS FOR USE IN THE TREATMENT OR PREVENTION OF PAIN | POSEIDA THERAPEUTICS INC (US) | 2018-08-29 | — | — | EP | claimed |
| US-9511117-B2 | Treatment of muscular conditions and muscular dystrophies | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-12-06 | — | — | US | claimed |
| US-20140256644-A1 | Treatment of Muscular Conditions and Muscular Dystrophies | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | claimed |
| WO-2013078261-A1 | TREATMENT OF MUSCULAR CONDITIONS AND MUSCULAR DYSTROPHIES | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2013-05-30 | — | — | WO | claimed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| EP-3485889-B1 | TRPC4 MODULATORS FOR USE IN THE TREATMENT OR PREVENTION OF PAIN | POSEIDA THERAPEUTICS INC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023108053-A1 | COMPOSITIONS FOR AND METHODS OF TREATING HEREDITARY AORTOPATHIES | DUKE UNIVERSITY (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023088620-A1 | CYCLIC BIARYL PHOSPHINES AS LIGANDS FOR PALLADIUM-CONTAINING CATALYSTS IN CROSS-COUPLING REACTIONS | Heraeus Deutschland GmbH & Co. KG (DE) | 2023-05-25 | — | — | WO | disclosed |
| EP-4180440-A1 | CYCLIC BIARYLPHOSPHINES AS LIGANDS FOR PALLADIUM-CONTAINING CATALYSTS IN CROSS-COUPLING REACTIONS | Heraeus Deutschland GmbH & Co. KG (DE) | 2023-05-17 | — | — | EP | disclosed |
| US-11241442-B2 | Methods of use for TRP channel antagonist-based combination cancer therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210311075-A1 | METHODS FOR DETECTING DISORDERS RELATED TO CALCIUM DISCHARGE FROM INTRACELLULAR STORES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2018165034-A1 | METHODS OF USE FOR TRP CHANNEL ANTAGONIST-BASED COMBINATION CANCER THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-09-13 | — | — | WO | disclosed |
| EP-2790687-B1 | TRPC4 MODULATORS FOR USE IN THE TREATMENT OR PREVENTION OF PAIN | POSEIDA THERAPEUTICS INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9511117-B2 | Treatment of muscular conditions and muscular dystrophies | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140329856-A1 | METHOD OF TREATING PAIN | POSEIDA THERAPEUTICS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140329856-A1 | METHOD OF TREATING PAIN | POSEIDA THERAPEUTICS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140256644-A1 | Treatment of Muscular Conditions and Muscular Dystrophies | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | disclosed |
| WO-2013090722-A1 | TRPC4 MODULATORS FOR USE IN THE TREATMENT OR PREVENTION OF PAIN | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013078261-A1 | TREATMENT OF MUSCULAR CONDITIONS AND MUSCULAR DYSTROPHIES | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | KDM4E 4338/4885GAA 27/4885L3MBTL1 4285/4885 |
| US-10131634-B2 | Method of treating pain | TRPC4, TRPV1, TRPC3 | KDM4E 3144/4885GAA 3574/4885L3MBTL1 2254/4885 |
| US-20140329856-A1 | METHOD OF TREATING PAIN | TRPC4, TRPV1, TRPC3 | KDM4E 3144/4885GAA 3574/4885L3MBTL1 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.